Treatment strategies in MDA5-positive clinically amyopathic dermatomyositis: a single-center retrospective analysis

• DOI: 10.1007/s10238-024-01300-8
• Publication Date: 2024-02-17T11:04:27Z
• Authors: Stefanie Hirsch; Gesa Helen Pöhler; Benjamin Seeliger; Antje Prasse; Torsten Witte; Thea Thiele
• Keywords: Male; Interferon-Induced Helicase, IFIH1; Research; Tacrolimus; Dermatomyositis; 03 medical and health sciences; 0302 clinical medicine; Humans; Female; Rituximab; Lung Diseases, Interstitial; Retrospective Studies; Autoantibodies

AbstractMelanoma differentiation-associated protein 5 (MDA5) antibody positive amyopathic dermatomyositis (DM) is a rare inflammatory disease. So far, there is no official treatment guideline in MDA5 amyopathic dermatomyositis, but early and aggressive immunosuppressive combination treatment can induce a stable remission. We retrospectively analyzed a cohort of eight patients (male n = 5) that were diagnosed with MDA5-positive amyopathic DM. Patient data comprised demographics, CT-guided diagnosis of pulmonary involvement, pulmonary function testing including forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) data on baseline and mean long-term follow-up of 51 months (24–92 months) to evaluate treatment strategies. Depending on severity of organ involvement treatments were individualized including cyclophosphamide, immunoglobulins and plasmapheresis. Simultaneously, oral treatment with tacrolimus was commenced in four of the eight patients. Most patients received remission maintenance therapy with a combination of tacrolimus, rituximab and low dose steroids. In all patients, improvement in FVC was recorded and five patients achieved an improvement in DLCO. An improvement in the CT imaging morphological findings was observed in four patients. Awareness for the entirety of all clinical and disease-related findings of amyopathic DM is crucial, and remission maintenance is often achieved with a combination of tacrolimus and rituximab.